RESEARKA

Grip strength longevity, as a research construct, sits at the intersection of muscle physiology, geriatric medicine, and public health. The measure itself is inexpensive, portable, and highly reproducible, making it attractive for large-scale screening. Clinically, the European Working Group on Sarcopenia in Older People established sex-specific cutoffs—27 kg for men and 16 kg for women—that are now widely used to define probable sarcopenia and trigger further evaluation (Cruz-Jentoft 2019). Below these thresholds, individuals face elevated risk of falls, disability, and postoperative complications; for instance, grip strength appears to predict anastomotic leakage after colorectal surgery (Weak 2026) and postoperative delirium in orthopedic and oncologic populations (Arita 2021, Lee 2026). Yet grip strength is not a drug; it is a biomarker, and the leap from observational association to therapeutic target requires evidence that modifying the biomarker changes the outcome. Whether grip strength longevity interventions—resistance training, nutritional supplementation, or emerging pharmacological approaches—can achieve clinically meaningful improvements in survival remains uncertain.

Citation Support

• source_1 Jayanama 2022
• source_2 TurBoned 2026
• source_3 Karahan 2026
• source_4 Cui 2021
• source_5 Aksoy 2026